U.S. VAERS Data From Dec. 14, 2020, to April 15, 2022, for 5- to 11-Year-Olds Show:
- 10,290 adverse events, including 248 rated as serious and 5 reported deaths.
- 19 reports of myocarditis and pericarditis (heart inflammation). The CDC uses a narrowed case definition of “myocarditis,” which excludes cases of cardiac arrest, ischemic strokes and deaths due to heart problems that occur before one has the chance to go to the emergency department.
- 40 reports of blood clotting disorders.
U.S. VAERS Data From Dec. 14, 2020, to April 15, 2022, for 12- to 17-Year-Olds Show:
- 31,113 adverse events, including 1,796 rated as serious and 43 reported deaths.
- 65 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases attributed to Pfizer’s vaccine.
- 651 reports of myocarditis and pericarditis, with 639 cases attributed to Pfizer’s vaccine.
- 166 reports of blood clotting disorders, with all cases attributed to Pfizer.
U.S. VAERS Data From Dec. 14, 2020, to April 15, 2022, for All Age Groups Combined, Show:
- 20% of deaths were related to cardiac disorders.
- 54% of those who died were male, 41% were female and the remaining death reports did not include the gender of the deceased.
- The average age of death was 73.
- As of April 15, 5,429 pregnant women reported adverse events related to COVID vaccines, including 1,701 reports of miscarriage or premature birth.
- Of the 3,633 cases of Bell’s Palsy reported, 52% were attributed to Pfizer vaccinations, 40% to Moderna and 8% to J&J.
- 861 reports of Guillain-Barré syndrome, with 42% of cases attributed to Pfizer, 30% to Moderna and 28% to J&J.
- 2,355 reports of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- 1,672 reports of myocardial infarction.
- 13,733 reports of blood-clotting disorders in the U.S. Of those, 6,166 reports were attributed to Pfizer, 4,914 reports to Moderna and 2,653 reports to J&J.
- 4,131 cases of myocarditis and pericarditis with 2,532 cases attributed to Pfizer, 1,408 cases to Moderna and 181 cases to J&J’s COVID vaccine.
1 in 10 Surveyed Doctors Believe COVID Shots Aren’t SafeOne in 10 primary care physicians don’t agree COVID vaccines are safe, and 9.3% don’t believe the vaccines are effective, according to a survey published in the April issue of Vaccine.
- The COVID vaccines are safe.
- The COVID vaccines are effective.
- The COVID vaccines are important.
The survey was conducted between May 14 and May 25, 2021.
769 Athletes Collapsed This Year During CompetitionMore than 769 athletes have collapsed on the field during a game from March 2021 to March 2022. The statistic was revealed by One America News Network (OAN), which also found the average age of the athletes who suffered cardiac arrest is just 23 years old.
The unprecedented surge in cardiac arrest and other heart issues among elite athletes coincides with the rollout of COVID vaccines.
“How many 23-year-old athletes were collapsing and suffering heart attacks before this year? Do you know any 23-year-old people who had heart attacks before now? And these are just the ones we know about.
“How many have gone unreported? Nearly 800 athletes — young, fit people in the prime of life — falling down on the field. In fact, 500% more soccer players in the EU are dropping dead from heart attacks than just one year ago.
“Coincidence? When the Pfizer vaccine is known to cause heart inflammation? No. In fact, many doctors treating these players list their injuries and deaths as being directly caused by the vaccine … This is not a coincidence.”
CDC Meets to ‘Mull Over’ Next Steps for COVID BoostersThe CDC’s vaccine advisory committee met Wednesday to “mull over” what’s next for COVID boosters and consider “upgrades” to the vaccines, The Defender reported.
Sara Oliver, one of the CDC’s epidemic intelligence service officers with the Division of Viral Diseases, said the evolution of the virus will be an important consideration for considering “platforms” for future COVID vaccinations.
Novavax Announces Early Data on COVID and Influenza Combo VaccineVaccine maker Novavax on Wednesday announced that early data on its combination vaccine targeting COVID and influenza showed the vaccine produced a strong immune response.
Participants in the Phase 1 trial had a median age of 59 and all previously had received COVID vaccines. Novavax plans to move forward with a Phase 2 trial this year to confirm the appropriate dosing levels, and plans to launch a Phase 3 trial on efficacy during the 2023 flu season at the earliest, Dubovsky said.
Novavax’s COVID vaccine does not use mRNA technology but synthesizes the virus spike outside the human body.
The vaccine also uses a novel adjuvant that contains a purified extract from the bark of a tree in South America, to induce a broader immune response.